Please Wait
Applying Filters...
menu
    • menu
    Evonik

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

    Virtual Booth

    Contact Supplier

    Temad- We think of world-class quality.

    Virtual Booth

    Contact Supplier

    Menu

    Nerandomilast

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    ERS Data: Nerandomilast Lowers Death Risk in IPF, PPF
    ERS Data: Nerandomilast Lowers Death Risk in IPF, PPF

    30 Sep 2025

    // PHARMAWEB

    https://www.pharmiweb.com/press-release/2025-09-30/pooled-data-presented-at-ers-nerandomilast-monotherapy-linked-to-nominally-significant-reduction-in-risk-of-death-in-ipf-and-ppf

    PHARMAWEB
    30 Sep 2025
    Share Share
    Boehringer's phase 3 lung data get muted response from analysts
    Boehringer's phase 3 lung data get muted response from analysts

    20 May 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/not-game-changing-boehringers-phase-3-lung-data-get-muted-response-analysts

    FIERCE BIOTECH
    20 May 2025
    Share Share
    Boehringer widens fibrosis drug's potential after 2nd ph. 3 win
    Boehringer widens fibrosis drug's potential after 2nd ph. 3 win

    11 Feb 2025

    // PRESS RELEASE

    https://www.boehringer-ingelheim.com/human-health/lung-diseases/pulmonary-fibrosis/nerandomilast-primary-endpoint-phase-3-fibroneer-ild-pulmonary-fibrosis

    PRESS RELEASE
    11 Feb 2025
    Share Share